MedTrace Logo

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis

NCT01684345 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-04-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis.

Conditions

  • Uveitis

Interventions

DRUG

Placebo

Solution for subcutaneous injection

DRUG

Dose 1 gevokizumab

Solution for subcutaneous injection

DRUG

Dose 2 gevokizumab

Solution for subcutaneous injection

Sponsors & Collaborators

  • Institut de Recherches Internationales Servier

    collaborator OTHER

  • XOMA (US) LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2016-02-29

Countries

  • United States
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Brazil
  • China
  • France
  • Germany
  • Greece
  • Israel
  • Mexico
  • Poland
  • Portugal
  • Russia
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Tunisia
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01684345 on ClinicalTrials.gov